A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis

References

• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–970.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Kaeley GS, Eder L, Aydin SZ, et al. Dactylitis: A hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:263–273.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis; development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Harron M, Gallagher P, Fitzgerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–1050.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifilogr. 2009;100:14–21.
   PubMedGoogle Scholar
• Favier G, Gladman D, Merola JF, et al. Benchmarking care in psoriatic arthritis – the QUANTUM report: a report from GRAPPA 2016 annual meeting. J Rheumatol. 2017;44:674–678.
   PubMedGoogle Scholar
• Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory disease: a hypothesis paper. J Dermatolog Treat. 2015;26:103–112.
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Palazzi C, Gilio M, et al. Improvements in diagnostic tools for early detection of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12:1209–1215.
   PubMed Web of Science ®Google Scholar
• Audureau E, Roux F, Lons Danic D, et al. Psoriatic arthritis screening by the dermatologist: development and first validation of the ‘PURE-4 scale’. J Eur Acad Dermatol Venereol. 2018;32:1950–1953.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venerol. 2018;32:515–528.
   PubMed Web of Science ®Google Scholar
• Mease P, Gladman D, Papp K, et al. The prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–735.
   PubMed Web of Science ®Google Scholar
• Poppengborg RP, Østergaardd M, Terslev L. Imaging in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:593–613.
   PubMed Web of Science ®Google Scholar
• Luchetti MM, Benfaremo D, Campanati A, et al. Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic. Clin Rheumatol. 2018;37:2741–2749.
   PubMed Web of Science ®Google Scholar
• Baum EW, Schwartzman S. ALIGN PsA: advancing a Multidisciplinary Approach in PsA. Semin Cutan Med Surg. 2018;37:S125–34.
   PubMedGoogle Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861–867.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5:566–574.
   PubMedGoogle Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29:645–648.
   PubMed Web of Science ®Google Scholar
• Smolen S, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77:3–17.
   PubMed Web of Science ®Google Scholar
• Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489–2498.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071.
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1–70.
   PubMed Web of Science ®Google Scholar
• Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12:743–750.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76:377–390.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–790.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Girolomoni G, Gisondi P. Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission. Br J Dermatol. 2019;181:1319–1320.
   PubMed Web of Science ®Google Scholar
• de Stefano R, Frati E, de Quattro D, et al. Low doses of etanercept can be effective to maintain remission in psoriatic arthritis patients. J Clin Rheumatol. 2018;24:127–131.
   PubMed Web of Science ®Google Scholar
• Nash P, Clegg DO. Psoriatic arthritis therapy: nSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64:74–77.
   Google Scholar
• Quan M. Hot topics in primary care: the cardiovascular safety of nonsteroidal anti-inflammatory drugs: putting the evidence in perspective. J Fam Pract. 2017;66:S52–7.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Ueng J, et al. Predictors response to intra-articular steroid injection in psoriatic arthritis. Rheumatology. 2010;49:1367–1373.
   PubMed Web of Science ®Google Scholar
• Combe B, Goupille P, Kuntz JL, et al. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996;35:664–668.
   PubMedGoogle Scholar
• Kingsley GH, Kowalcyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51:1368–1377.
   PubMed Web of Science ®Google Scholar
• Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43:356–361.
   PubMed Web of Science ®Google Scholar
• Merola JF, Ogdie A. SEAM-PsA: seems like methotrexate works in psoriatic arthritis? Arthritis Rheumatol. 2019;71:1027–1029.
   PubMed Web of Science ®Google Scholar
• Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175:23–44.
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Mash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheumatol. 2004;50:1939–1950.
   PubMed Web of Science ®Google Scholar
• Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-months nonrandomized unblinded clinical trial. J Rheumatol. 2011;38:2466–2474.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702–709.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleishmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostegaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65:1213–1223.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723–738.
   PubMed Web of Science ®Google Scholar
• Kawalec P, Holko P, Moćko P, et al. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoritic arthritis: a systematic review and network meta-analysis. Rheumatol Int. 2018;38:189–201.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13:751–755.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int J Mol Sci. 2017;18:2427.
   PubMed Web of Science ®Google Scholar
• Combe B, Behrens F, McHugh N, et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43:1063–1067.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Collier DH, Saunders KC, et al. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;30:1.
   Google Scholar
• Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:723–738.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Englbrecht M, Hoepken S, et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48:632–637.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Perrotta FM. The role of IL-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2017;13:815–821.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Sondag M, Verhoeven F, Guillot X, et al. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. Clin Rheumatol. 2018;38:591–596.
   PubMed Web of Science ®Google Scholar
• Strand V, McInnes I, Mease P, et al. Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. J Comp Eff Res. 2019;8:497–510.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–356.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific antibody, for the treatment of biology-naïve patients with active psoriatic arthritis: results from the 24-weeks randomised, double-blinde, placebo-controlled and active (adalimumab)-controlled period of phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317–2327.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79:123-131.
   Web of Science ®Google Scholar
• Gladmann DD, Orbai AM, Klitz U, et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019;21:38.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–1073.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic arthritis. N Engl J Med. 2017;377:1537–1550.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167:668–677.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology. Current evidence and future applications. J Dermatolog Treat. 2019;30:648–658.
   PubMed Web of Science ®Google Scholar
• Verden A, Dimbil M, Kyle R, et al. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41:357–361.
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatcept in the treatment of patients with psoriatic arthritis: results of a six-month, multicentre, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939–948.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550–1558.
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: implications for management. J Am Acad Dermatol. 2017;76:393–403.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Tardif JC, Harel F, et al. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging. 2013;6:83–90.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Osto E, Famoso G, et al. Treatment with tumor necrosis factor inhibitors restores coronary microvascular function in young patients with severe psoriasis. Atherosclerosis. 2016;251:25–30.
   PubMed Web of Science ®Google Scholar
• von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol. 2019;139:1054–1062.
   PubMed Web of Science ®Google Scholar
• Cantini F, Benucci M, Li Gobbi F, et al. Biosimilars for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2019;15:1195–1203.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391:2213–2224.
   PubMed Web of Science ®Google Scholar
• Maroof A, Beaten D, Archer S, et al. IL-17F contributes to human chronic inflammation in synovial tissue: preclinical evidence with dual IL-17A and IL-17F inhibition with bimekizumab in psoriatic arthritis. Ann Rheum Dis. 2017;76:A13.
   Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523–532.
   PubMed Web of Science ®Google Scholar
• Boutet M, Nerviani A, Pitzalis C. IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: a comprehensive review of their therapeutic potential. Int J Mol Sci. 2019;20:1257.
   Web of Science ®Google Scholar